Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Bispecific GD2xB7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma.bioRxiv : the preprint server for biology · 2026Article
- Phase I Study ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Correlations of FCGR2A 131R/H and FCGR3A 158V/F Polymorphisms with the Susceptibility of Peri-implantitis in Chinese Han Population.Molecular biotechnology · 2025Article
- A Comprehensive Review of Fc Gamma Receptors and Their Role in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025Review
- Article
- Deciphering Molecular Mechanisms of Cutaneous Leishmaniasis, Pathogenesis and Drug Repurposing through Systems BiologyIranian biomedical journal · 2024Article
- BAG3 as a novel prognostic biomarker in kidney renal clear cell carcinoma correlating with immune infiltrates.European journal of medical research · 2024Article
- Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.Cancer immunology, immunotherapy : CII · 2023Article
- KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group.Journal for immunotherapy of cancer · 2023Article
- Overview of Research on Germline Genetic Variation in Immune Genes and Cancer Outcomes.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Systematic Analysis of the Expression and Prognosis of Fcγ Receptors in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2022Article
- NK Cell-Based Immunotherapy in Renal Cell Carcinoma.Cancers · 2020Review
- HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Wei WangDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Jacob GoldbergDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Mikayla GallenbergerDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
KyungMann KimDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Lakeesha CarmichaelDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Dustin HessDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Eneida A MendoncaDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Yiqiang SongDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin.
Jacquelyn A HankDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin.
Su-Chun ChengDepartment of Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts.
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Michael AtkinsThe Cytokine Working Group.
Alexander CarlsonDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
James W MierThe Cytokine Working Group.
David J PankaDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
David F McDermottThe Cytokine Working Group.
Paul M SondelDepartment of Human Oncology, University of Wisconsin, Madison, Wisconsin. pmsondel@humonc.wisc.edu.
Brigham and Women's Hospital · US
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MUW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2MECOG Statistical Office Data Management GrantU10CA066636 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI GRAY, ROBERT J · 1994 to 2013
$39.5MPROVIDE STATISTICAL SERVICESU10CA023318 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, ROBERT J · 1985 to 2013
$33.4MEASTERN COOPERATIVE ONCOLOGY GROUP--WISCONSIN STUDIESU10CA021076 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI KAHL, BRAD · 1985 to 2013
$8.2MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MNational Clinical Trials Network Research at the University of WisconsinU10CA180799 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI ANDERSON, BETHANY M, KUSHNER, DAVID M · 2014 to 2018
$2.8MStanford University NCTN- Network Lead Academic SiteU10CA180816 · NCI · STANFORD UNIVERSITY · PI COUTRE, STEVEN EDWARD, LE, QUYNH-THU XUAN · 2014 to 2018
$2.8MONCOLOGYU10CA014958 · NCI · YESHIVA UNIVERSITY · PI SPARANO, JOSEPH A. · 1985 to 2013
$2.2MThe Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 ImmunotherapyR01CA166105 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2012 to 2014
$987kNCI NIH HHS P30 CA014520NCI NIH HHS R01 CA166105NCI NIH HHS R35 CA197078NCI NIH HHS U10 CA014958NCI NIH HHS U10 CA021076NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA023318NCI NIH HHS U10 CA066636NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180799NCI NIH HHS U10 CA180816NCI NIH HHS U10 CA180820
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adaptive ImmunityAdultAgedCarcinoma, Renal CellDisease-Free SurvivalFemaleGenetic Association StudiesGenotypeHumansImmunity, InnateInterleukin-2MaleMiddle AgedNeoplasm MetastasisPolymorphism, Single NucleotideReceptors, IgGaldesleukinFCGR2A protein, humanFCGR2C protein, humanFCGR3A protein, humanInterleukin-2Receptors, IgGRecombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.